

## Correction to Appendix 3Y

HeraMED Limited (ASX:HMD) ('HeraMED' or the 'Company') wishes to make a correction to the Appendix 3Y that was lodged on 28 March 2024.

On it was erroneously stated that Mr. David Hinton participated in a *placement*. We wish to rectify this error and clarify that Mr. David Hinton actually participated in the *rights issue*, not the placement as previously mentioned.

We are now submitting an amended Appendix 3Y that correctly reflects Mr. David Hinton's participation in the *rights issue*.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

**CEO**

Anoushka Gungadin  
T: +61 431 131 649  
E: [anoushka@hera-med.com](mailto:anoushka@hera-med.com)

**CFO & Company Secretary**

Cameron Jones  
E: [cameron.jones@bio101.com](mailto:cameron.jones@bio101.com)

**Investor Relations**

Tim Chapman  
T: +61 419 897 062  
E: [tchapman@claritycap.com.au](mailto:tchapman@claritycap.com.au)

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	HERAMED LIMITED
<b>ABN 65 626 295 314</b>	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	DAVID HINTON
<b>Date of last notice</b>	23 July 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	In-Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	David Ayers Hinton and Heather Joy Hinton <Bromilow Account> of which Mr Hinton is a trustee and beneficiary
<b>Date of change</b>	28 February 2024
<b>No. of securities held prior to change</b>	358,333 Ordinary Fully Paid Shares
<b>Class</b>	Ordinary Fully Paid Shares
<b>Number acquired</b>	71,667
<b>Number disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$1,433.34
<b>No. of securities held after change</b>	430,000 Ordinary Fully Paid Shares

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in rights issue announced to the market on 28 February 2024
---	---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.